• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies.

作者信息

Bárcena-Varela Marina

机构信息

Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA; Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; The Precision Immunology Institute Department, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

出版信息

J Hepatol. 2022 Jul;77(1):9-11. doi: 10.1016/j.jhep.2022.04.020. Epub 2022 May 2.

DOI:10.1016/j.jhep.2022.04.020
PMID:35513202
Abstract
摘要

相似文献

1
Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies.揭示肝癌中抗程序性死亡蛋白1（PD-1）耐药机制：通向新型联合免疫疗法之路。
J Hepatol. 2022 Jul;77(1):9-11. doi: 10.1016/j.jhep.2022.04.020. Epub 2022 May 2.
2
Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.肝脏免疫耐受与肝细胞癌：病理生理机制及治疗前景
Eur J Cancer. 2017 Dec;87:101-112. doi: 10.1016/j.ejca.2017.10.010. Epub 2017 Nov 13.
3
Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.抗 PD-1/PD-L1 阻断免疫疗法治疗乙型肝炎病毒感染相关的晚期肝细胞癌：文献综述。
Front Immunol. 2020 May 28;11:1037. doi: 10.3389/fimmu.2020.01037. eCollection 2020.
4
Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.肝动脉灌注化疗联合抗PD-1免疫疗法及酪氨酸激酶抑制剂治疗晚期肝细胞癌的真实世界研究
Immunotherapy. 2021 Dec;13(17):1395-1405. doi: 10.2217/imt-2021-0192. Epub 2021 Oct 5.
5
Recent developments with immunotherapy for hepatocellular carcinoma.肝细胞癌免疫治疗的最新进展。
Expert Opin Biol Ther. 2018 Aug;18(8):905-910. doi: 10.1080/14712598.2018.1499722. Epub 2018 Jul 20.
6
Immunotherapy for hepatocellular carcinoma.肝细胞癌的免疫治疗。
Cancer Lett. 2020 Feb 1;470:8-17. doi: 10.1016/j.canlet.2019.12.002. Epub 2019 Dec 4.
7
Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.新辅助程序性细胞死亡 1（PD-1）抑制剂治疗肝癌患者肝移植前：队列研究和文献复习。
Front Immunol. 2021 Jul 19;12:653437. doi: 10.3389/fimmu.2021.653437. eCollection 2021.
8
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.提高免疫疗法治疗肝细胞癌抗肿瘤效果的策略。
Front Immunol. 2021 Nov 26;12:783236. doi: 10.3389/fimmu.2021.783236. eCollection 2021.
9
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.免疫检查点抑制剂联合治疗肝细胞癌的挑战。
J Hepatol. 2020 Feb;72(2):307-319. doi: 10.1016/j.jhep.2019.09.025.
10
[Advances in the study of programmed cell death protein 1 and its ligand inhibitors in the treatment of late stage HCC].程序性细胞死亡蛋白1及其配体抑制剂在晚期肝癌治疗中的研究进展
Zhonghua Gan Zang Bing Za Zhi. 2019 Sep 20;27(9):732-736. doi: 10.3760/cma.j.issn.1007-3418.2019.09.017.

引用本文的文献

1
Serum amyloid A promotes glycolysis of neutrophils during PD-1 blockade resistance in hepatocellular carcinoma.血清淀粉样蛋白 A 促进 PD-1 阻断耐药性肝细胞癌中中性粒细胞的糖酵解。
Nat Commun. 2024 Feb 26;15(1):1754. doi: 10.1038/s41467-024-46118-w.
2
Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma.外泌体来源的 circCCAR1 促进肝癌中 CD8+T 细胞功能障碍和抗 PD1 耐药性。
Mol Cancer. 2023 Mar 18;22(1):55. doi: 10.1186/s12943-023-01759-1.